ArticleMolecular biology reports2025
The impact of supplementation with iso-branched chain fatty acids in a mouse model of atherosclerosis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSerum iso-branched chain fatty acids (iso-BCFAs) levels are inversely correlated with triglyceride and high-sensitivity C-reactive protein (hs-CRP) concentration in obese patients. Moreover, they decrease the expression of genes related to lipogenesis and inflammation in hepatocytes. However, their role in atherosclerosis development remains unclear. This study aimed to assess the impact iso-BCFA supplementation on hyperlipidaemia and inflammation in atherosclerotic apolipoprotein E and low-density lipoprotein receptor double knockout (ApoE
methodsApoE
resultsBCFA supplementation led to a stable increase in serum and tissue levels of these FAs. Significant reduction in serum triglyceride and total cholesterol (TC) concentrations was observed in the BCFA-fed group. No change in body weight or serum CRP was detected, whereas the mRNA levels of Il6 in liver were lower after BCFA treatment. However, vascular lipid content and eADA activity were higher in BCFA-fed mice, and hepatic Cpt1 mRNA expression significantly increased, suggesting enhanced β-oxidation.
conclusionsDietary iso-BCFA supplementation may modulate lipid metabolism in ApoE
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.